Potential use of human serum albumin as a drug delivery systems
Human serum albumin has recently emerged as a versatile carrier for therapeutic agents against diabetes, cancer and infectious diseases. Market approved products include fatty acid derivatives of human insulin or the glucagon-like-1 peptide (Levemir®) for the treatment of diabetes, a long-acting inj...
| Main Authors: | , , |
|---|---|
| Format: | Book Chapter |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/16797 |
| _version_ | 1848749279959580672 |
|---|---|
| author | Ishima, Y. Maruyama, T. Otagiri, Masaki |
| author_facet | Ishima, Y. Maruyama, T. Otagiri, Masaki |
| author_sort | Ishima, Y. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Human serum albumin has recently emerged as a versatile carrier for therapeutic agents against diabetes, cancer and infectious diseases. Market approved products include fatty acid derivatives of human insulin or the glucagon-like-1 peptide (Levemir®) for the treatment of diabetes, a long-acting injectable human interferon alpha2b fusion protein (Albuferon®) for the potential treatment of hepatitis C virus infections, and the taxol albumin nanoparticle Abraxane® for the treatment of metastatic breast cancer, advanced non-small cell lung cancer and advanced pancreatic cancer. In addition, an increasing number of albumin-based drugs are currently in clinical trials. These include an antibody fusion protein for treating HER2/neu positive breast cancer, and a recombinant fusion protein linking factor IX with albumin for the Prophylaxis of hemophilia B. In the preclinical setting, next generation approaches include albumin binding bioactive gases (bio-Gas) such as nitric oxide or hydrogen sulfide (S-Nitrosated Albumin analogs and Albumin Persulfide) for treating ischemic/reperfusion injury, cancer and bacterial infections. This review provides an overview of the expanding field of preclinical and clinical applications and developments that use albumin as a carrier of drug delivery systems. |
| first_indexed | 2025-11-14T07:18:25Z |
| format | Book Chapter |
| id | curtin-20.500.11937-16797 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T07:18:25Z |
| publishDate | 2015 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-167972017-11-02T05:04:38Z Potential use of human serum albumin as a drug delivery systems Ishima, Y. Maruyama, T. Otagiri, Masaki Human serum albumin has recently emerged as a versatile carrier for therapeutic agents against diabetes, cancer and infectious diseases. Market approved products include fatty acid derivatives of human insulin or the glucagon-like-1 peptide (Levemir®) for the treatment of diabetes, a long-acting injectable human interferon alpha2b fusion protein (Albuferon®) for the potential treatment of hepatitis C virus infections, and the taxol albumin nanoparticle Abraxane® for the treatment of metastatic breast cancer, advanced non-small cell lung cancer and advanced pancreatic cancer. In addition, an increasing number of albumin-based drugs are currently in clinical trials. These include an antibody fusion protein for treating HER2/neu positive breast cancer, and a recombinant fusion protein linking factor IX with albumin for the Prophylaxis of hemophilia B. In the preclinical setting, next generation approaches include albumin binding bioactive gases (bio-Gas) such as nitric oxide or hydrogen sulfide (S-Nitrosated Albumin analogs and Albumin Persulfide) for treating ischemic/reperfusion injury, cancer and bacterial infections. This review provides an overview of the expanding field of preclinical and clinical applications and developments that use albumin as a carrier of drug delivery systems. 2015 Book Chapter http://hdl.handle.net/20.500.11937/16797 restricted |
| spellingShingle | Ishima, Y. Maruyama, T. Otagiri, Masaki Potential use of human serum albumin as a drug delivery systems |
| title | Potential use of human serum albumin as a drug delivery systems |
| title_full | Potential use of human serum albumin as a drug delivery systems |
| title_fullStr | Potential use of human serum albumin as a drug delivery systems |
| title_full_unstemmed | Potential use of human serum albumin as a drug delivery systems |
| title_short | Potential use of human serum albumin as a drug delivery systems |
| title_sort | potential use of human serum albumin as a drug delivery systems |
| url | http://hdl.handle.net/20.500.11937/16797 |